Organogenesis Holdings Inc is Shariah compliant. The company passes all five major Shariah standards.
$770,907,169
Market cap
72.28%
Revenue Growth
STRONG BUY
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
Debt ÷ Market cap (MC) | 9.55% | ✓ |
Non-Compliant Assets ÷ MC | % |
S&P
S&P ✓
Debt ÷ 36 mo MC | 7.3% | ✓ |
Cash ÷ 36 mo MC | 11.29% | ✓ |
AR ÷ 36 mo MC | % |
DJIM
DJIM ✓
Debt ÷ 24 mo MC | 5.76% | ✓ |
Cash ÷ 24 mo MC | 8.92% | ✓ |
AR ÷ 24 mo MC | % |
FTSE
FTSE ✓
Debt ÷ Assets | 16.61% | ✓ |
Cash ÷ Assets | 25.7% | ✓ |
Cash&AR ÷ Assets | 25.7% | ✓ |
MSCI
MSCI ✓
Debt ÷ Assets | 16.61% | ✓ |
Cash ÷ Assets | 25.7% | ✓ |
Cash&AR ÷ Assets | 25.7% | ✓ |
Recommendation Rating
1
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 14
Low: 13
High: 15
Total Analysts: 3
Company Profile
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier for a variety of wound types, and the Affinity, Novachor and NuShield wound coverings to address a variety of wound sizes and types. Sports medicine products include NuShield for surgical application in soft tissue repairs, and Affinity, Novachor and PuraPly AM for management of open wounds in the surgical setting. It offers its products to a range of healthcare customers, including hospitals, wound care centers and physician offices.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses